載入中
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
前收盤價
US$229.23
+US$6.54 · +2.94%
盤中時間採用ET。市場資料可能有所延遲。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日內區間
目前US$229.23
52週區間
目前US$229.23
盤中時間採用ET。市場資料可能有所延遲。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日內區間
目前US$229.23
52週區間
目前US$229.23
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$317.42
上漲空間 38.47%報告持有此股票曝險的交易所交易基金。
T. Rowe Capital Appreciation Equity ETFTCAF1.7億1.88%91.1億 USD0.31%US$43.59+0.90%
iShares Biotechnology ETFIBB1.06億1.01%108.2億 USD0.44%US$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP6300.3萬0.32%200.95億 USD0.23%US$143.1+1.56%
iShares Russell Mid-Cap ETFIWR4930.98萬0.09%567.65億 USD0.18%US$109.82+0.87%
iShares Russell 1000 Growth ETFIWF4200.89萬0.03%1305.08億 USD0.18%US$127.91+0.63%
Sapient Quality Select ETFSQS3244萬2.28%14.24億 USD0.80%US$28.5901-0.24%
Vanguard Russell 1000 Growth ETFVONG2013.05萬0.04%543億 USD0.06%US$131.69+0.63%
First Trust Health Care AlphaDEX FundFXH1497.28萬1.34%11.13億 USD0.61%US$130.15+1.37%T. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFSapient Quality Select ETFSQSVanguard Russell 1000 Growth ETFVONGFirst Trust Health Care AlphaDEX FundFXHAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
